PulseExploreJournal ClubTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 13, 2026BMC CancerOpen Access

Efficacy and safety of concurrent chemoradiotherapy combined with immunotherapy for locally advanced esophageal squamous cell carcinoma: a retrospective cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

RLRong LiHHHe-qing HuangLYLi-hua Yang

Discussion

Loading...

Member takes

Overview

Retrospective cohort study evaluates treatment outcomes in patients with localized ESCC, suggesting improved survival with combined therapy.

Key Points

  • This study aims to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with immunotherapy in patients with locally advanced unresectable ESCC.
  • Retrospective cohort design involving 106 patients at Guangxi Medical University from July 2019 to December 2022.
  • Comparison of treatment outcomes between 60 patients receiving CCRT + IT and 46 patients receiving CCRT only.
  • Analysis of objective response rates, progression-free survival, overall survival, and adverse events.
  • CCRT + IT group had a significantly higher objective response rate (76.7% vs. 52.2%; p = 0.008).
  • 1-year progression-free survival was better in the CCRT + IT group (66.7% vs. 41.3%; p = 0.009).
  • 1-year overall survival was also higher in the CCRT + IT group (80.0% vs. 58.7%; p = 0.017).

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/6a0414f679e20c90b4444c7dhttps://doi.org/10.1186/s12885-026-16162-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma2024 · 4 citations
  2. 2Chemoradiotherapy with versus without concurrent immune checkpoint inhibitor for locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study2026 · 1 citations
  3. 3Neoadjuvant immunotherapy combined with concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A prospective, single-arm, phase II trial.2026
  4. 4Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study2024 · 19 citations
  5. 5Definitive chemoradiotherapy plus immune checkpoint inhibitors for locally advanced unresectable esophageal squamous cell carcinoma: survival and progression patterns in a propensity‐matched cohort2026